Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482428 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT02482428 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT02482428, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%. During the study the patients received either LFX453, placebo or active comparator and the tolerability and safety was assessed continuously through local tolerability assessments and adverse event recorded. Efficacy was clinical evaluations and lesion count. During the study biopsies were taken for analysis of pharmacokinetics and biomarkers. Blood samples were taken for safety, pharmacokinetics (PK), and biomarkers.
Interventions
- DRUG Investigational Treatment
- DRUG Aldara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2015-05-12 |
| Est. Completion | 2016-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02482428
The ClinicalTrials.gov registry entry for NCT02482428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Investigational Treatment is the first listed.
NCT02482428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02482428 about?
NCT02482428 is a clinical study titled "Efficacy and Tolerability of Topical LFX453 for External Genital Warts". The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%. During the study the patients received either LFX453, placebo or active...
What is the current status of trial NCT02482428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2015-05-12. Estimated completion is 2016-05-31.
What interventions are being tested in trial NCT02482428?
The interventions under investigation include: Investigational Treatment (DRUG), Aldara (DRUG).
Who is sponsoring clinical trial NCT02482428?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.